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BACKGROUND: Nifedipine is a widely used drug in pregnancies normalized, and normoxemia phase data were collected, while infusion
complicated by maternal hypertensive disorders that can be associated
with placental insufficiency and fetal hypoxemia. The evidence regarding
fetal myocardial responses to nifedipine in hypoxemia is limited.
OBJECTIVE: We hypothesized that nifedipine would not impair fetal
sheep cardiac function under hypoxemic environment. In particular, we
investigated the effects of nifedipine on fetal ventricular functional
parameters and cardiac output.
STUDY DESIGN: A total of 21 chronically instrumented fetal sheep at
122 to 134 gestational days (term, 145 days) were included in this study.
Fetal cardiac function was evaluated by measuring global longitudinal
strain, indices describing ventricular systolic and diastolic function, and
cardiac outputs using two-dimensional speckle tracking and tissue and
spectral pulsed-wave Doppler echocardiography. Fetal carotid artery blood
pressure and blood gas values were invasively monitored. After baseline
data collection, fetal hypoxemia was induced by maternal hyper-
oxygenation. After hypoxemia phase data collection, 9 fetuses received
nifedipine infusion, and 12 fetuses received saline infusion. Data were
collected 30 and 120 minutes after the infusion was started. After 120
minutes of data collection, maternal and fetal oxygenation wereCite this article as: Alanne L, Bhide A, Lantto J, et al.
Nifedipine disturbs fetal cardiac function during hypox-
emia in a chronic sheep model at near term gestation. Am
J Obstet Gynecol 2021;XX:x.exex.ex.
0002-9378
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open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
https://doi.org/10.1016/j.ajog.2021.04.228was continued.
RESULTS: Hypoxemia decreased fetal carotid artery mean arterial
pressure from 40 (8) mm Hg to 35 (8) mm Hg (P<.007), and left ven-
tricular global longitudinal strain showed less deformation than at baseline
(P¼.001). Under hypoxemia, nifedipine caused a reduction in right ven-
tricular global longitudinal strain (P<.05), a decrease in right ventricular
isovolumic relaxation velocity and its deceleration (P<.01) indicating
diastolic dysfunction, and a drop in right ventricular cardiac output
(P<.05). Nifedipine did not alter fetal left ventricular functional parameters
or cardiac output. When normoxemia was restored, fetal right ventricular
functional parameters and cardiac output returned to baseline level.
CONCLUSION: In hypoxemic fetus, nifedipine impaired right ventricular
function and reduced its cardiac output. The detrimental effects of nifedipine
on fetal right ventricular function were abolished, when normoxemia was
restored. Our findings suggest that in a hypoxemic environment nifedipine
triggers detrimental effects on fetal right ventricular function.
Key words: antihypertensive medication, blood flow, heart, hemody-
namics, hypertension, physiology, pregnancy, ultrasoundIntroduction
Nifedipine, a dihydropyridine calcium
channel blocker, is a commonly used
drug in pregnancies complicated by
maternal hypertensive disorders. Espe-
cially in preeclampsia, placental impair-
ment is a common finding that can
hamper fetal oxygenation and other gas
exchange. Placental transfer of nifedi-
pine to the fetal circulation is substantial
because the umbilical cord serum con-
centration of nifedipine is approximately
93% of corresponding maternal serum
concentration.1 Studies on sheep haveshown that maternally administered
nifedipine does not affect fetal blood
pressure. However, it can impair uterine
blood flow, potentially resulting in fetal
hypoxemia and acidemia.2 In human
fetuses, maternally administered nifedi-
pine has no detectable effect on uterine
or umbilical artery blood flow velocity
waveforms obtained by Doppler ultra-
sonography.3 Furthermore, we have
shown that nifedipine when given
directly to fetal circulation under
hypoxemia does not alter placental he-
modynamics or umbilical artery blood
flow velocity waveform.4
Myocardial contractility depends on
multiple factors that include the amount
of contractile proteins, Ca2þ, the sensi-
tivity of the troponin-tropomyosin sys-
tem to changes in Ca2þ concentration
within the cell, and the interaction be-
tween actin and myosin.5 Nifedipine
reduces developed pressure in immature
rabbit heart at substantially lowerMONTH 2021 Amconcentrations than required in the
adult heart.6 The age-related differences
in mechanical function to calcium an-
tagonists suggest that contractile force in
the neonatal heart is more dependent on
the slow inward calcium current than in
the adult heart.5 In addition, electro-
physiological studies using a mouse
heart have shown a higher sensitivity of
ventricular L-type Ca2þ channel current
to verapamil in neonatal and infant
stages than in child and adult stages.7
These results suggest that myocardial
responsiveness to calcium channel
blockers changes with maturation and
age. In addition, the evidence concerning
fetal myocardial responses to calcium
channel blockers in hypoxemic envi-
ronment is limited. Therefore, we
designed a chronically instrumented
fetal sheep model to investigate the effect
of nifedipine on fetal cardiac function
when the fetus is hypoxemic. We
hypothesized that nifedipine when givenerican Journal of Obstetrics & Gynecology 1.e1
AJOG at a Glance
Why was this study conducted?
Nifedipine is a commonly used drug in pregnancies complicated by maternal
hypertensive disorders. Despite its widespread use during pregnancy, the possible
detrimental effects of nifedipine on fetal cardiac function, especially during
hypoxemia, are not fully investigated. In a chronically instrumented sheep model,
we studied whether nifedipine impacts on fetal cardiac function under
hypoxemia.
Key findings
Under hypoxemia, nifedipine decreased global longitudinal strain, was related to
signs of diastolic dysfunction, and ultimately reduced cardiac output in the fetal
right ventricle (RV).
What does this add to what is known?
In hypoxemic environment, nifedipine can have detrimental effects on fetal RV
function that is the dominant ventricle during the second half of pregnancy.
Original Research OBSTETRICS ajog.orgdirectly to the fetus would not have
detrimental effect on fetal cardiac func-
tion during hypoxemia. In particular, we
investigated the effect of nifedipine on
fetal left (LV) and right ventricular (RV)
(1) global longitudinal strain, (2) indices
describing ventricular systolic and dia-
stolic function, and (3) cardiac outputs.
Materials and Methods
In this study, we included 21 sheep of
Finnish breed with time-dated
pregnancies. The study protocol was
approved by the National Animal
Experiment Board of Finland (ESAVI/
1007/04.10.07/ 2014). The animal care
and experimental procedures were
conducted according to the national
legislation8,9 and the European Union
Directive 2010/63/EU.10
Fetal instrumentation
Fetal instrumentation was performed at
117 to 130 gestational days (term, 145
days) under general anesthesia induced
with intravenous propofol (4e7 mg/kg)
and maintained with isoflurane (1.5% to
2.5%) in an oxygen-in-air mixture
delivered via an endotracheal tube. For
pain relief, intravenous boluses of fen-
tanyl (0.05e0.15 mg) were administered
when required.
After a midline laparotomy and a
small hysterotomy, fetal head and upper
body were delivered. Polyvinyl catheters
were introduced into the external jugular1.e2 American Journal of Obstetrics & Gynecologyvein and the carotid artery placing the
catheter tips in the superior vena cava
and carotid artery. A 3-lead 28-gauge
silver-coated copper electrocardiogram
wire (New England Wire Tech, Lisbon,
NH) was attached subcutaneously on the
fetal chest. A separate polyvinyl catheter
was placed in the amniotic cavity to
monitor intraamniotic pressure. The lost
amniotic fluid was replaced with warm
0.9% saline solution. All incisions were
closed, and the fetus received an intra-
amniotic injection of penicillin G (1
million units). All catheters and wires
were tunneled to a pouch on the ewe’s
flank. Postoperative pain was controlled
with oxycodone given via an epidural
catheter that was placed to the ewe
before the surgery.
Experimental protocol
After a 4- to 5-day recovery, experiments
were performed under general anes-
thesia induced with a single bolus of
propofol and maintained by isoflurane
in an oxygen-in-air mixture. The depth
of anesthesia was titrated to minimize its
effect on maternal heart rate and blood
pressure and allow for ultrasound
examination without discomfort. A 16-
gauge polyurethane catheter was inser-
ted into the maternal femoral artery.
Thereafter, the ewe was placed supine
with a right lateral tilt and allowed to
stabilize for 30 minutes before obtaining
the baseline measurements. AfterMONTH 2021baseline measurements were collected,
the ewe was connected to a rebreathing
circuit to induce maternal and fetal
hypoxemia. Maternal fraction of
inspired oxygenwas reduced to reach the
peripheral oxygen saturation level of
80%. This was confirmed by maternal
arterial blood gas values. Hypoxemia
phase data (hypoxemia) were collected
30 minutes after the desired maternal
oxygen saturation level was reached.
After hypoxemia phase data collection
was completed, 9 fetuses were allocated
to receive nifedipine infusion at a rate of
1.0 mL/h (700 mg/mL) (5 mg/kg/min)
into the superior vena cava. The nifedi-
pine dose was based on the studies by
Blea et al11 and Nugent et al12 and is
approximately equivalent to maternal
oral intake of 10 mg nifedipine.1 In the
control group, 12 fetuses received saline
infusion. Data were collected at 30
(hypoxemiaþ30 minute infusion) and
120 (hypoxemiaþ120 minute infusion)
minutes after commencement of infu-
sion. After hypoxemiaþ120 minute
infusion phase data collection was
completed, maternal oxygenation was
returned to baseline level while infusion
was continued. Maternal normoxemia
was achieved within 3minutes. Recovery
phase data collection (normox-
emiaþinfusion) was started 30 minutes
after maternal normoxemia was ach-
ieved (Figure 1). Themean infusion time
was approximately 150 minutes in each
group, and the calculated total mean
dose of nifedipine was 1.75 mg. The
steady state of the nifedipine concen-
tration in the fetal circulation is achieved
in 30 to 40 minutes after maternal
infusion.1,11 The total dose of nifedipine
in this study is equivalent to an oral
administration of 10mg nifedipine given
5 times during a 2-hour period. The
animals were euthanized at the end of
the experiment with an intravenous
overdose (100 mg/kg) of pentobarbital
sodium to the fetus and ewe. Fetal
weights were determined postmortem.
Monitoring protocol
Maternal and fetal arterial blood
pressures were continuously monitored
with disposable pressure transducers
(DT-XX, Ohmeda, Hatfield, United
FIGURE 1
Timeline of the experiment
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were referenced to intraamniotic pres-
sure.Maternal heart rate was determined
from the arterial pressure waveforms.
Fetal electrocardiogram leads were con-
nected to the ultrasound equipment to
obtain fetal heart rate. Maternal and fetal
blood gas values were corrected to 39C
and analyzed at each study point using
an Abbot i-Stat 1 arterial blood gas
analyzer (i-Stat, East Windsor, NJ).
Ultrasonographic data acquisition
Doppler ultrasonography was per-
formed at the end of each phase by a
single investigator (J.R.) using a Vivid 7
Dimension ultrasound system (GE
Vingmed Ultrasound AS, Horten, Nor-
way) with a 10 MHz-phased array
transducer. The high-pass filter was set atminimum, and the angle of insonation
was kept below 15 degrees. Ultrasono-
graphic images were analyzed offline by a
single observer (L.A.) blinded to alloca-
tion of animals to nifedipine or control
groups.
Cine-loop images of 4-chamber views
were obtained. Myocardial deformation
(strain) was obtained by two-
dimensional speckle tracking to assess
ventricular systolic function.13 Cine-loop
clips of the ultrasound examination were
stored digitally. Further processing and
measurements were performed using an
image data acquisition software (Echo-
PAC, GE Medical Systems, CA).
Myocardial global longitudinal strainwas
measured for the LV and RV in a 4-
chamber view. An automated tracking
algorithm outlined the myocardium inMONTH 2021 Amconsecutive frames in the cardiac cycle. If
needed, the manual adjustment of the
region of interest was performed. The
mean value of the 2 measurements was
used for analysis.
Tissue Doppler technique was applied
to measure LV and RV lateral wall
movements at the atrioventricular valve
level during the cardiac cycle. The sam-
ple volume (1e1.5 mm) was placed at
the level of the atrioventricular valve
annuli and aligned as parallel as possible
to the myocardial wall (<15 angle of
insonation). Myocardial velocities were
recorded during 3 to 6 cardiac cycles at a
sweep speed of 100 mm/s. Isovolumic
relaxation (IVRV) and contraction
velocities (IVCV) of the LV and RV free
wall were measured. Fetal cardiac
diastolic function was evaluated usingerican Journal of Obstetrics & Gynecology 1.e3
Original Research OBSTETRICS ajog.orgthe deceleration of IVRV (IVRVdec).
Systolic function was assessed by the
acceleration of IVCV (IVCVacc).
14,15 To
calculate fetal cardiac outputs, the
diameters of the aortic (AoV) and pul-
monary (PV) valves were measured in
frozen real-time images during systole
with the leading-edge to leading-edge
method. The mean value of 3 separate
valve diameter measurements was used
to calculate the cross-sectional area
(CSA) of the valve. From the blood flow
velocity waveforms of the AoV and PV,
time-velocity integrals (TVI) were
measured and volumetric blood flows
(Q) across the AoV and PV were calcu-
lated (Q¼CSATVIfetal heart rate).16
LV cardiac output (LVCO) equals the
AoV volumetric blood flow and RV
cardiac output (RVCO) equals the PV
volumetric blood flow, and their sum is
the combined cardiac output. Fetal
cardiac outputs were weight indexed.
Statistical analysis
Linearmixedmodel (LMM)was used for
repeatedly measured data. The phase of
the experiment and infusion of nifedi-
pine vs saline were included as fixed ef-
fects, an interaction term, and individual
fetus as the random intercept. If LMM
showed a significant difference between
measurement points (p(time)<0.05),
then a pairwise comparison between
relevant points was performed. The
difference between the groups was
expressed as p(group). The groups may
not show similar changes with time
(interaction term). Therefore, this was
expressed as p(group*time). Statistical
analyses were performed using SPSS
(IBM Corp. Released 2011. IBM SPSS
Statistics for Windows, Version 25.
Armonk, NY). Data are presented as
mean and standard deviation (SD) un-
less stated otherwise. Two-tailed P<.05
was considered statistically significant.
Results
Maternal arterial blood pressure and
heart rate remained within normal
physiological range in both groups dur-
ing the experiment. Reduction in
maternal pO2 during hypoxemia phases
was comparable between the groups
(data not indicated). Mean fetal weight1.e4 American Journal of Obstetrics & Gynecologywas 2.44 (2.00e2.99) kg and 2.51
(2.06e2.80) kg (P¼.51) in the control
and nifedipine groups, respectively. The
experiments were done at the mean
gestational age of 128 (SD, 2) and 126
(SD, 5) days in the control and nifedipine
groups (P¼.37), respectively.
At baseline, LV global longitudinal
strain showed more deformation
(P¼.001) than RV global longitudinal
strain. Other ultrasonographic parame-
ters describing ventricular systolic and
diastolic function or cardiac outputs did
not differ between LV and RV.
During hypoxemia phase, fetal pO2
decreased (P<.001) compared with
baseline (Table 1). Other fetal blood gas
values remained comparable with base-
line level. Fetal mean arterial pressure
(MAP) decreased (P<.007) compared
with baseline (Table 1). LV global lon-
gitudinal strain demonstrated less
deformation (P¼.01) than at baseline
(Table 2). Fetal tissue Dopplerederived
indices of LV and RV systolic and dia-
stolic function did not change signifi-
cantly during hypoxemia phase
compared with the baseline. Further-
more, fetal cardiac outputs did not differ
from the baseline values.
In hypoxemiaþ30 minute infusion
phase, fetal pO2 (P<.001) and base
excess (P<.001) were lower and lactate
(P<.001) concentrations higher than at
baseline (Table 1). Both LV and RV
global longitudinal strains did not
change significantly from the hypoxemia
phase values (Table 2). In the nifedipine
group, LV IVCV (P¼.02), RV IVRV
(P<.001), and its deceleration (P<.001)
were lower than at baseline. In the con-
trol group, RV IVCVacc (P¼.003) was
significantly lower than the baseline with
no difference between the groups
(Table 2). In both groups, LV and RV
cardiac outputs did not differ from the
baseline values (Table 2).
In hypoxemiaþ120 minute infusion
phase, fetal blood gas values were com-
parable with hypoxemiaþ30 minute
infusion phase (Table 1). In the nifedi-
pine group, RV global longitudinal strain
showed less deformation than at baseline
(P¼.03) or compared with the control
group (P¼.02) (Table 2). In addition, LV
IVCV (P¼.003), and RV IVRV (P<.001),MONTH 2021and its deceleration (P¼.001) were less
than at baseline in fetuses receiving
nifedipine (Table 2). Furthermore, in the
nifedipine group, RVCO was lower than
hypoxemia (P<.05) and hypoxemiaþ30
minute infusion (P<.05) phases as well
as in the control group fetuses (P<.05)
(Table 2, Figure 2). In the control group,
fetal cardiac parameters remained
comparable with the previous phase.
In normoxemiaþinfusion phase, fetal
pO2 was lower (P<.05) in the nifedipine
group than in the control group. In the
nifedipine group, fetal LV and RV
global longitudinal strains, tissue
Dopplerederived indices of fetal cardiac




Our focus was to investigate the effect of
nifedipine on fetal cardiac function
during hypoxemia.We gave nifedipine to
fetal circulation, to study its direct effect
on fetal cardiac function rather than
those that are secondary to changes in
maternal cardiovascular and uteropla-
cental hemodynamics. Nifedipine
infusion was associated with impaired
fetal RV function that manifested as
reduced global longitudinal strain,
decreased IVRVdec suggesting diastolic
dysfunction, and finally as a drop in the
RV output. These alterations cannot be
explained by an increase in the afterload
because fetal MAP decreased during
hypoxemia. After fetal hypoxemia was
reversed, fetal cardiac functional
parameters in the nifedipine group were
comparable with baseline values sug-
gesting that hypoxemic environment
triggers the detrimental effects of
nifedipine on fetal RV function.
Results in the context of what is
known
At baseline with fetal normoxemia, LV
global longitudinal strain showed more
deformation than the corresponding RV
strain that is in agreement with previous
observations.17,13 Under hypoxemia, LV
global longitudinal strain showed less
deformation than during normoxemia,
whereas hypoxemia had no effect on RV
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MONTH 2021 Amglobal longitudinal strain during
hypoxemia could be a consequence of a
drop in LV preload, direct myocardial
dysfunction caused by hypoxemia, or a
combination of the 2.13 During nifedi-
pine infusion, RV global longitudinal
strain showed a reduction in deforma-
tion, whereas the corresponding LV
global longitudinal strain was not
affected. However, during normoxemia
phase when nifedipine infusion was
continued, RV global longitudinal strain
returned to baseline level. Our results
suggest that nifedipine can have a detri-
mental effect on fetal RV function,
especially when the fetus is hypoxemic.
However, hypoxemia itself did not seem
to alter RV global longitudinal strain,
because in the control group it remained
unchanged. Ventricular longitudinal
strain is affected by ventricular loading
conditions. In human fetuses, RV global
longitudinal strain shows less deforma-
tion with advancing gestational age.18
This is proposed to reflect increased RV
afterload, that is, fetal blood pressure
that increases with advancing gestation.
In the present study, fetal MAP
decreased during hypoxemia; thus, the
effect of reduced afterload on RV global
longitudinal strain should have been the
opposite. Therefore, we believe that the
reduction in RV global longitudinal
strain was a direct effect of nifedipine
itself and reflected deteriorated RV
systolic function.
We found that, in fetuses who received
nifedipine infusion, RV IVRV and its
deceleration decreased. These parame-
ters assess the movement of the ven-
tricular lateral wall during early diastole,
when the intraventricular pressure de-
creases from the systemic to atrial level.
The IVRVdec describes the ventricular
diastolic function. The myocardial
relaxation is an active process requiring
energy to transport Ca2þ from cytosol
into the sarcoplasmic reticulum. The
release of Ca2þ from the sarcoplasmic
reticulum is more a passive process
requiring less energy.19 Therefore,
diastolic function is impaired earlier and
to a greater extent than systolic function
if the energy supply is limited.
Under hypoxemia, fetal RVCO
decreased in fetuses who receivederican Journal of Obstetrics & Gynecology 1.e5
TABLE 2












FHR (bpm) 171 (31) 167 (21) Control 162 (27) 176 (16) 144 (25) 0.54 0.046 0.10
Nifedipine 156 (22) 158 (32) 159 (28)
Global longitudinal strain (%)
Left ventricle 17.1(3.6)a 14.4 (2.8) Control 14.4 (3.0) 12.7 (4.1) 16.7 (2.6) 0.62 0.017a 0.21
Nifedipine 14.6 (3.0) 14.3 (4.1) 15.3 (3.1)
Right ventricle 13.9 (3.6) 12.4 (3.1) Control 12.6 (3.4) 13.7 (3.8) 14.8 (2.2) 0.046a 0.18 0.52
Nifedipine 11.8 (3.4) 9.7 (3.1)b 11.9 (2.7)
Diastolic function
Left ventricle
IVRV (cm/s) 2.63 (1.04) 2.36 (0.91) Control 2.39 (0.94) 2.90 (1.46) 2.79 (1.31) 0.18 0.30 0.32
Nifedipine 2.03 (0.95) 1.95 (0.69) 2.70 (1.13)
IVRVdec (cm/s
2) 3.40 (2.52) 2.39 (0.85) Control 2.39 (0.94) 3.09 (1.83) 2.23 (0.76) 0.74 0.07 0.22
Nifedipine 2.03 (0.95) 2.08 (0.77) 3.37 (0.94)
Right ventricle
aIVRV (cm/s) 3.33(1.23) 2.65 (1.13) Control 2.42 (0.98) 2.94 (1.45) 2.90 (1.11) 0.068 0.001a 0.009a
Nifedipine 2.59 (1.13) 2.23 (0.50) 2.97 (0.48)
IVRVdec (cm/s
2) 3.05 (2.03) 2.17 (0.84) Control 2.19 (0.88) 2.51 (1.64) 1.97 (1.23) 0.46 0.008a 0.007a
Nifedipine 2.47 (1.05) 2.75 (1.04) 3.02 (1.28)
Systolic function
Left ventricle
IVCV (cm/s) 7.34 (3.67) 6.15 (3.21) Control 6.12 (2.26) 6.34 (3.51) 7.01 (2.63) 0.60 0.021a 0.40
Nifedipine 5.14 (1.38) 4.47 (0.93) 7.85 (3.76)
IVCVacc (cm/s
2) 5.40 (2.04) 4.25 (1.57) Control 4.50 (1.65) 5.40 (1.54) 4.89 (2.30) 0.62 0.20 0.28
Nifedipine 4.55 (2.07) 3.59 (1.11) 6.41 (4.69)
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MONTH 2021 Amnifedipine infusion. Ventricular output
depends on diastolic and systolic func-
tion and ventricular loading conditions.
Fetal sheep studies have shown that
RVCO can increase during hypoxemia.20
In addition, it seems that fetal RV can
maintain its function better than the LV
during worsening hypoxemia and acid-
emia.21 In sheep fetuses with increased
placental vascular resistance and acute
metabolic acidosis, RV and LV global
cardiac function is preserved.14
Furthermore, in human fetuses with
severe placental insufficiency and signs
of increased systemic venous pressure,
weight-indexed combined fetal cardiac
output is comparable with the fetuses
with uncomplicated pregnancies.22
Based on these findings, we propose
that reduced RVCO in the nifedipine
group during hypoxemia is a result of
nifedipine itself. Interestingly, these
detrimental effects of nifedipine on fetal
RV function disappeared when fetal
normoxemia was restored.
Clinical and research implications
Nifedipine is widely used in pregnancies
complicated by maternal hypertensive
disorders. From a clinical perspective, it
is important to know the possible unfa-
vorable effects of nifedipine on the fetus,
especially on fetal cardiac function. This
experimental model was developed to
investigate the drug effects on the
hypoxemic fetus, because placental
insufficiency and fetal hypoxemia are
commonly seen in pregnancies compli-
cated by maternal hypertensive disor-
ders. The main finding that nifedipine
disturbs fetal RV function and ultimately
RVCO is clinically important, because in
fetal circulation the RV is responsible for
the blood flow in the fetal lower body
and placenta. Furthermore, RV is the
dominant ventricle in the fetal circula-
tion during the second half of pregnancy
carrying more than 50% of fetal com-
bined cardiac output.16 Our results
suggest that hypoxemia is needed to
trigger the detrimental effects of nifedi-
pine on fetal RV, because during nor-
moxemia and nifedipine infusion RV
functional parameters and RV cardiac
output were restored. We propose that
human fetuses who have hypoxemia anderican Journal of Obstetrics & Gynecology 1.e7
FIGURE 2
Fetal RVCO in the control and nifedipine groups during the experiment
RVCO, right ventricular cardiac output.
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Original Research OBSTETRICS ajog.orga significant placental insufficiency, that
is, abnormal umbilical artery blood flow
pattern, could be more vulnerable to the
detrimental effects of nifedipine on fetal
cardiac function. Previously, we found
that beta-blockers can differently affect
fetal RV and LV, that is, maternal
administration of pindolol decreased
fetal LVCO and induced vasoconstric-
tion in the pulmonary vasculature.23 The
next step in experimental researchwould
be to mimic placental insufficiency
by embolizing placental vasculature to
increase placental vascular resistance.
Then we could explore whether nifedi-
pine had more detrimental effect on
cardiac function when hypoxemia is
associated with significant placental
insufficiency. In addition, we have to
determine themechanistic pathways that
lead to fetal cardiac dysfunction after
nifedipine administration. Finally, it is
important to investigate human fetal
cardiac function to understand whether
the response to nifedipine will be similar
to sheep fetuses.
Strengths and limitations
The main strengths of our study include
that we gave the nifedipine infusion
directly into the fetal circulation in
relevant concentration to investigate its
effects on cardiac function to avoid those1.e8 American Journal of Obstetrics & Gynecologyalterations that could be secondary to
changes in maternal hemodynamics. In
addition, we used multiple different and
independent ultrasonographic modal-
ities that are validated in previous studies
to examine cardiac function.13,15,16
Our study has certain limitations.
Fetal surgical intervention could consti-
tute a major stress. However, the recov-
ery period after surgery should be long
enough for full recovery of fetal cardio-
vascular physiology as evidenced by
normal blood gas values at baseline.24
The experiments were performed
under general anesthesia that could
modify fetal cardiovascular responses to
hypoxemia. However, the cardiovascular
system of the newborn lamb can increase
oxygen delivery in response to hypox-
emia during isoflurane anesthesia. At
reasonable anesthetic depth and without
myocardial or peripheral cardiovascular
disease, the newborn lamb can coordi-
nate neural, endocrine, and local tissue
responses to increase cardiovascular
performance in hypoxemia.25 Finally,
validation studies in sheep fetuses have
proven that invasive and Doppler echo-
cardiographic volume blood flow calcu-
lations correlate well.26 The
intraobserver variabilities of Doppler
ultrasonographic parameters of fetal
sheep cardiovascular hemodynamics areMONTH 2021comparable with those found in human
fetuses during the second half of
pregnancy.27,28
Conclusion
We conclude that, under hypoxemic
conditions, nifedipine impaired fetal
RV function that manifested as reduced
global longitudinal strain, diastolic
dysfunction, and a drop in the RV
output. After recovery from hypoxemia,
cardiac functional parameters in fetuses
receiving nifedipine were comparable
with baseline values. This suggests that
hypoxemic environment triggers the
detrimental effects of nifedipine on fetal
RV function. nReferences
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